Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, Hockaday, AM et al. (7 more authors) (2016) Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17. 456. ISSN 1745-6215

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: CLL; Chronic Lymphocytic Leukaemia; Ofatumumab; FC; Bendamustine; Phase II trial; MRD; Minimal Residual Disease; Dose selection; Relapsed population; Randomised clinical trial
Dates:
  • Accepted: 16 August 2016
  • Published: 20 September 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:
FunderGrant number
GlaxoSmithKlineCRT115386
Depositing User: Symplectic Publications
Date Deposited: 06 Sep 2016 09:42
Last Modified: 05 Oct 2017 16:22
Published Version: https://dx.doi.org/10.1186/s13063-016-1581-0
Status: Published
Publisher: BioMed Central
Identification Number: https://doi.org/10.1186/s13063-016-1581-0

Share / Export

Statistics